Shanai Song

16 Jiangsu Road
Qingdao, 266003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.

Journal: Human vaccines & immunotherapeutics

Published: January 08, 2026

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.

Journal: Therapeutic advances in medical oncology

Published: January 04, 2026

A case report: Achieving complete response in synchronous primary lung and tongue squamous cell carcinomas through the integration of albumin-bound paclitaxel, cisplatin, and tislelizumab.

A case report: Achieving complete response in synchronous primary lung and tongue squamous cell carcinomas through the integration of albumin-bound paclitaxel, cisplatin, and tislelizumab.

Journal: Human vaccines & immunotherapeutics

Published: December 05, 2025

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.

Journal: Human vaccines & immunotherapeutics

Published: September 09, 2025

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.

Journal: Frontiers in immunology

Published: May 08, 2025

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.

Journal: Frontiers in oncology

Published: April 18, 2025

Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study.

Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study.

Journal: World journal of surgical oncology

Published: August 05, 2024

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.

Journal: World journal of surgical oncology

Published: March 17, 2024

Retraction Note: Bifidobacterium plays a protective role in TNF-α-induced inflammatory response in Caco-2 cell through NF-κB and p38MAPK pathways.

Retraction Note: Bifidobacterium plays a protective role in TNF-α-induced inflammatory response in Caco-2 cell through NF-κB and p38MAPK pathways.

Journal: Molecular and cellular biochemistry

Published: February 29, 2024

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.

Journal: Discover oncology

Published: January 31, 2024

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.

Journal: Journal of translational medicine

Published: October 22, 2022

Cost-efficiency tradeoff is optimized in various cancer types revealed by genome-wide analysis.

Cost-efficiency tradeoff is optimized in various cancer types revealed by genome-wide analysis.

Journal: Molecular genetics and genomics : MGG

Published: October 09, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026